Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 5/20 | 0.43 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802075 | 0.81 | POLB (0.47) | POLBCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL104891 | 0.80 | P2RX3 (0.54) | POLBCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL6556332 | 0.80 | L3MBTL1 (0.53) | POLBCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL9702616 | 0.78 | P2RX3 (0.53) | POLBCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL5697814 | 0.78 | CA1 (0.55) | L3MBTL1GAANPSR1ALDH1A1KDM4E | |
| SCHEMBL6516593 | 0.78 | ACHE (0.46) | POLBPPARGPPARANPSR1ALDH1A1 | |
| SCHEMBL10601649 | 0.78 | POLB (0.48) | POLBCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL3162462 | 0.76 | POLB (0.47) | POLBCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL8333706 | 0.76 | POLB (0.52) | POLBCYP1A2CYP2C9CYP2C19L3MBTL1 | |
| SCHEMBL1010865 | 0.76 | POLB (0.52) | POLBCYP1A2CYP2C9CYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242103-B2 | Sulphamides for treatment of cancer | MERCK SHARP & DOHME LIMITED (GB) | 2012-08-14 | — | — | US | disclosed |
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| EP-1885349-A2 | SULPHAMIDES FOR TREATMENT OF CANCER | Merck Sharp & Dohme Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| EP-1268412-B8 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006123185-A2 | SULPHAMIDES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| EP-1268412-B1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-7138400-B2 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-21 | — | — | US | disclosed |
| EP-1334085-B1 | SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2005-08-24 | — | — | EP | disclosed |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-03-11 | — | — | US | disclosed |
| US-5051447-A | Applying aromatic oximes to plants, seeds or soils | BASF AKTIENGESELLSCHAFT (DE) | 1991-09-24 | — | — | US | disclosed |
| US-4997973-A | Ortho-substituted benzyl carboxylates and fungicides containing these compounds | BASF AKTIENGESELLSCHAFT (DE) | 1991-03-05 | — | — | US | disclosed |
| EP-0310954-B1 | ORTHO-SUBSTITUTED CARBOXYLIC ACID BENZYL ESTERS AND FUNGICIDES CONTAINING THESE COMPOUNDS | BASF Aktiengesellschaft (DE) | 1990-11-22 | — | — | EP | disclosed |
| US-4952720-A | Ortho-substituted benzyl carboxylates and fungicides which contain these compounds | BASF AKTIENGSELLSCHAFT (DE) | 1990-08-28 | — | — | US | disclosed |
| EP-0337211-B1 | ORTHO-SUBSTITUTED CARBOXYLIC-ACID BENZYL ESTERS AND FUNGICIDES CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1990-07-11 | — | — | EP | disclosed |
| EP-0354571-A1 | Oximethers, method for their preparation and fungicides containing them | BASF Aktiengesellschaft (DE) | 1990-02-14 | — | — | EP | disclosed |
| EP-0337211-A1 | Ortho-substituted carboxylic-acid benzyl esters and fungicides containing them | BASF Aktiengesellschaft (DE) | 1989-10-18 | — | — | EP | disclosed |
| EP-0310954-A1 | Ortho-substituted carboxylic acid benzyl esters and fungicides containing these compounds | BASF Aktiengesellschaft (DE) | 1989-04-12 | — | — | EP | disclosed |
| US-4701452-A | STIMULANTS; ANTIBIOTICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-10-20 | — | — | US | disclosed |
| US-4454129-A | ANTIBIOTICS, BACTERICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | SDHA, SDHB, BRDT | POLB 1080/4885CYP1A2 1359/4885CYP2C9 1086/4885 |
| US-20040049038-A1 | Sulfamides as gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | POLB 2081/4885CYP1A2 2373/4885CYP2C9 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.